HCW Biologics Inc. SEC filings HCWB
HCW Biologics Inc. has 341 filings in SEC EDGAR's recent list, going back to Oct 19, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (material agreement, regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 9, 2026 | — |
| D | Filing | Oct 8, 2026 | — |
| PRER14A | Filing | Sep 9, 2026 | — |
| EFFECT | Filing | Aug 31, 2026 | — |
| CORRESP | Letter to the SEC | Aug 28, 2026 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2026 | — |
| D | Filing | Aug 6, 2026 | — |
| EFFECT | Filing | Jun 18, 2026 | — |
| CORRESP | Letter to the SEC | Jun 16, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 12, 2026 | — |
| D | Filing | Jun 8, 2026 | — |
| EFFECT | Filing | Apr 29, 2026 | — |
| DRS | Filing | Apr 13, 2026 | — |
| EFFECT | Filing | Feb 17, 2026 | — |
| CORRESP | Letter to the SEC | Feb 11, 2026 | — |
| CORRESP | Letter to the SEC | Feb 11, 2026 | — |
| EFFECT | Filing | Jan 29, 2026 | — |
| CORRESP | Letter to the SEC | Jan 27, 2026 | — |
| DRS | Filing | Dec 19, 2025 | — |
| DRS | Filing | Oct 1, 2025 | — |
| NT 10-Q | Filing | Aug 15, 2025 | Jun 30, 2025 |
| EFFECT | Filing | May 13, 2025 | — |
| CORRESP | Letter to the SEC | May 13, 2025 | — |
| CORRESP | Letter to the SEC | May 9, 2025 | — |
| UPLOAD | Letter from the SEC | May 1, 2025 | — |
| DRS | Filing | Apr 28, 2025 | — |
| EFFECT | Filing | Apr 16, 2025 | — |
| CORRESP | Letter to the SEC | Apr 15, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2025 | — |
| CT ORDER | Filing | Feb 26, 2025 | — |
| DEFR14A | Filing | Feb 26, 2025 | — |
| D | Filing | Dec 5, 2024 | — |
| ARS/A | Filing | May 20, 2024 | Dec 31, 2023 |
| D | Filing | Feb 27, 2024 | — |
| EFFECT | Filing | Aug 26, 2022 | — |
| CORRESP | Letter to the SEC | Aug 25, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 24, 2022 | — |
| EFFECT | Filing | Jul 19, 2021 | — |
| CORRESP | Letter to the SEC | Jul 16, 2021 | — |
| CORRESP | Letter to the SEC | Jul 16, 2021 | — |
| CORRESP | Letter to the SEC | Jul 15, 2021 | — |
| SEC STAFF LETTER | Filing | Jul 15, 2021 | — |
| CERT | Filing | Jul 15, 2021 | — |
| CORRESP | Letter to the SEC | Jul 13, 2021 | — |
| CORRESP | Letter to the SEC | Jul 13, 2021 | — |
| 8-A12B | Filing | Jul 9, 2021 | — |
| SEC STAFF LETTER | Filing | Jun 22, 2021 | — |
| CORRESP | Letter to the SEC | Jun 15, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 10, 2021 | — |
| CORRESP | Letter to the SEC | Jun 4, 2021 | — |
| CORRESP | Letter to the SEC | May 26, 2021 | — |
| UPLOAD | Letter from the SEC | May 13, 2021 | — |
| DRS | Filing | Apr 16, 2021 | — |
| D | Filing | Oct 19, 2020 | — |
Showing 54 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HCWB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miramar, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1828673
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.